- Home
- MSD vs UNCY Comparison
MSD vs UNCY Comparison
Compare MSD & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MSD | UNCY |
|---|---|---|
| Founded | 1993 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.9M | 150.1M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MSD | UNCY |
|---|---|---|
| Price | $7.26 | $5.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $25.67 |
| AVG Volume (30 Days) | 42.2K | ★ 691.1K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 11.26% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $675,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $582.86 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.91 | $3.72 |
| 52 Week High | $7.94 | $8.74 |
Technical Indicators
Market Signals| Indicator | MSD | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 50.62 | 44.33 |
| Support Level | $7.23 | $4.81 |
| Resistance Level | $7.44 | $5.86 |
| Average True Range (ATR) | 0.06 | 0.21 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 27.79 | 14.90 |
Price Performance
Historical ComparisonAbout MSD Morgan Stanley Emerging Markets Debt Fund Inc.
Morgan Stanley Emerg Mkts Debt Fd Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to produce high current income and as a secondary objective to seek capital appreciation, through investments mainly in debt securities of government and government-related issuers located in emerging countries, of entities organized to restructure the outstanding debt of such issuers and debt securities of corporate issuers in or organized under the laws of emerging countries.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.